Skip to main content

Table 1 Patient characteristics

From: Feasibility study of docetaxel plus bevacizumab as first line therapy for elderly patients with advanced non-small-cell lung cancer: Thoracic Oncology Research Group (TORG) 1014

Category

Subcategory

Level 0, N

Level -1, N

Total

 

9

12

Median age (range), yr

 

78 (74–79)

75 (70–84)

Sex

Female

5

7

 

Male

4

5

Histological type

Adenocarcinoma

8

11

 

NSCLC, NOS

1

1

Disease stage

IIIB

1

1

 

IV

8

10

 

Recurrent

0

1

Performance status

0

3

5

 

1

6

7

EGFR mutation

Ex19 del

0

2

 

L858R

2

0

 

Wild type

5

7

 

Unknown

2

3

  1. EGFR: Epidermal growth factor receptor, Ex19del: Exon 19 deletions, NOS: Not otherwise specified, NSCLC: Non-small-cell lung cancer